# Case report and literature review: Golidocitinib as a potential treatment for monomorphic epitheliotropic intestinal T-cell lymphoma

## TL;DR

This paper reports three cases of a rare aggressive lymphoma and suggests a new treatment combining Golidocitinib with chemotherapy may improve patient outcomes.

## Contribution

The novel contribution is the potential use of Golidocitinib, a JAK-1 inhibitor, in combination therapy for MEITL.

## Key findings

- Younger patients, those with intestinal perforation, and those without chemotherapy had worse prognoses.
- Combining Golidocitinib with GDP regimen improved patient prognosis by targeting the JAK-STAT pathway.

## Abstract

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare type of non-Hodgkin lymphoma and a highly aggressive malignancy with a median overall survival of 7 months. Meanwhile, owing to the complex and confusing symptoms including nonspecific gastrointestinal symptoms, systemic manifestations and additional clinical manifestations associated with the extraintestinal involvement organs, MEITL is often diagnosed at an advanced stage. We report three cases of MEITL, and searched PubMed indexed articles between 2016 and 2024 for these terms: “MEITL” and “case report”. We found that younger patients, those with intestinal perforation, and those who did not receive chemotherapy had worse prognoses. Importantly, we found that treatment with the JAK-1 inhibitor Golidocitinib in combination with the GDP regimen (Gemcitabine, Dexamethasone and Cisplatin) can improve patient prognosis. The study suggests that Golidocitinib could potentially improve the prognosis of MEITL patients by targeting the JAK-STAT pathway, although further validation of its long-term effectiveness is needed.